Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

11.60p
   
  • Change Today:
    -0.78p
  • 52 Week High: 17.60p
  • 52 Week Low: 1.09p
  • Currency: UK Pounds
  • Shares Issued: 502.72m
  • Volume: 3,961,499
  • Market Cap: £58.32m
  • RiskGrade: 328

Dividends

Year End Type Amount Payment Date Ex-Div Date Record Date
31-Dec-20 Interim 00.00      
  Final 00.00      

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Historical interim dividends and record dates not previously collected

Note 4: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Immupharma Market Data

Currency UK Pounds
Share Price 11.60p
Change Today -0.78p
% Change -6.26 %
52 Week High 17.60p
52 Week Low 1.09p
Volume 3,961,499
Shares Issued 502.72m
Market Cap £58.32m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average
21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average
Price Trend
67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average
40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 24-Oct-2025

Time Volume / Share Price
16:30 77 @ 10.70p
16:30 125 @ 10.70p
16:30 112 @ 10.70p
16:30 64 @ 11.80p
15:50 100,000 @ 10.95p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page